<h4>Background</h4>Metastatic colorectal cancer (CRC) harboring KRAS mutations presents a major therapeutic challenge due to its aggressive nature, poor prognosis, and resistance to EGFR-targeted therapies. Here, EGFR is linked to colorectal carcinoma.